Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion NutravedaBOM:544694 21 Market Cap is ₹2,055.8 Mil as of Aug. 01, 2026. GuruFocus rates BOM:544694 with a GF Score™ of 21/100. The stock has 3 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Accretion Nutraveda ranks worse than 78.13% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Accretion Nutraveda's share price for the quarter that ended in Mar. 2026 was ₹207.95. Accretion Nutraveda's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 7.2 Mil. Therefore, Accretion Nutraveda's market cap for the quarter that ended in Mar. 2026 was ₹1,505.6 Mil.
Accretion Nutraveda's quarterly market cap
stayed the same
from Mar. 2025 (₹0.0 Mil) to Sep. 2025 (₹0.0 Mil) but then
increased
from Sep. 2025 (₹0.0 Mil) to Mar. 2026 (₹1,505.6 Mil).
Accretion Nutraveda's annual market cap
stayed the same
from Mar. 2024 (₹0.0 Mil) to Mar. 2025 (₹0.0 Mil) but then
increased
from Mar. 2025 (₹0.0 Mil) to Mar. 2026 (₹1,505.6 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Accretion Nutraveda's Enterprise Value for Today is ₹2,085.3 Mil.
Accretion Nutraveda (BOM:544694) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Accretion Nutraveda Market Cap Related Terms
Accretion Nutraveda Market Cap Historical Data
* Premium members only.
The historical data trend for Accretion Nutraveda's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda Market Cap Chart
Accretion Nutraveda Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
Market Cap
0.00
0.00
0.00
1,505.56
Accretion Nutraveda Semi-Annual Data
Mar23
Mar24
Mar25
Sep25
Mar26
Market Cap
0.00
0.00
0.00
0.00
1,505.56
BOM:544694 vs ZTS: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Accretion Nutraveda's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Nutraveda Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Nutraveda's Market Cap distribution charts can be found below:
* The bar in red indicates where Accretion Nutraveda's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Accretion Nutraveda's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Nutraveda (BOM:544694) has a Market Cap of ₹2,055.8 Mil as of Aug. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Accretion Nutraveda and its competitors. According to the industry distribution chart, Accretion Nutraveda ranks #800 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 78.1%.
Is Accretion Nutraveda's Market Cap too high?
Accretion Nutraveda's current Market Cap is ₹2,055.8 Mil. Based on the distribution chart, Accretion Nutraveda ranks #800 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Nutraveda has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Nutraveda's Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Accretion Nutraveda ranks #800 out of 1024 companies for Market Cap. This places Accretion Nutraveda in the lower half of its industry. The industry median Market Cap is 210.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.63, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Accretion Nutraveda and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Nutraveda's current Market Cap is ₹2,055.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Nutraveda stock overvalued right now?
Accretion Nutraveda (BOM:544694) has a current Market Cap of ₹2,055.8 Mil. The current Market Cap is ₹2,055.8 Mil. Accretion Nutraveda's overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Accretion Nutraveda (BOM:544694), the current Market Cap is ₹2,055.8 Mil as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Nutraveda Ltd is engaged in the business of the Manufacturing of Ayurvedic and Nutraceutical products across several dosage forms, including Tablets, Capsules, Oral liquids, Oral Powders, External Preparation and Oils. It is a healthcare focused Company specializing in contract manufacturing, serving domestic as well as export markets in various countries like Sri Lanka, Singapore and the USA. The company offers a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. Its product portfolio includes Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.
21GF Score
Get the complete analysis for BOM:544694
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544694 has been successfully added to your 
